Glutamate is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Glutamate is the principal excitatory neurotransmitter in the mammalian [central nervous system], mediating the vast majority of fast excitatory synaptic transmission. Present in over 90% of all excitatory synapses, glutamate plays essential roles in [synaptic plasticity[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX--, learning, memory, and neural development. However, excessive glutamate signaling — a process termed excitotoxicity — is a major pathological mechanism contributing to neuronal death in virtually all neurodegenerative diseases, including [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [amyotrophic lateral sclerosis[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, and [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX-- (Meldrum, 2000; Dong et al., 2009).
Glutamate signaling operates through a complex system of ionotropic and metabotropic receptors, high-affinity transporters, and metabolic enzymes. Disruption of any component of this signaling system can shift the balance from physiological neurotransmission to pathological [excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity--TEMP--/entities)--FIX--, making glutamatergic dysfunction a central therapeutic target in neurodegeneration.
Glutamate homeostasis is maintained by the glutamate-glutamine cycle between [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--:
- Release: Glutamate is released from presynaptic vesicles into the synaptic cleft upon neuronal depolarization
- Uptake: [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- rapidly clear synaptic glutamate via excitatory amino acid transporters (EAATs), primarily EAAT1 (GLAST) and EAAT2 (GLT-1), which account for approximately 90% of glutamate reuptake (Danbolt, 2001)
- Conversion: In [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, glutamine synthetase converts glutamate to glutamine
- Recycling: Glutamine is released and taken up by [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, where glutaminase reconverts it to glutamate for repackaging into synaptic vesicles
Glutamate is synthesized through multiple pathways:
- From glutamine: Via mitochondrial glutaminase (the primary synaptic source)
- From α-ketoglutarate: Via aspartate aminotransferase (linking the TCA cycle to neurotransmission)
- From [GABA[/entities/[gaba[/entities/[gaba[/entities/[gaba--TEMP--/entities)--FIX--: Via GABA-transaminase (connecting excitatory and inhibitory neurotransmission)
- De novo synthesis: Via pyruvate carboxylase in [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- (the only CNS cell type capable of net glutamate synthesis)
Ionotropic glutamate receptors (iGluRs) are ligand-gated ion channels that mediate fast excitatory transmission:
[NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor] receptor] receptors] (N-methyl-D-aspartate) are heterotetrameric channels composed of obligatory GluN1 subunits combined with GluN2A-D or GluN3A-B subunits. Key features include:
- Voltage-dependent Mg²⁺ block: At resting potential, Mg²⁺ ions block the channel pore, requiring prior membrane depolarization for activation — making NMDARs coincidence detectors for presynaptic and postsynaptic activity
- Ca²⁺ permeability: High permeability to calcium makes NMDARs critical for both synaptic plasticity and excitotoxic neuronal death
- Co-agonist requirement: Glycine or D-serine binding to the GluN1 subunit is required for channel opening
- Slow kinetics: Prolonged channel opening and calcium influx compared to AMPA/kainate receptors
[NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor] receptor] receptor overactivation is the primary mediator of excitotoxic neuronal death. Excessive Ca²⁺ influx through NMDARs activates [calpains[/entities/[calpains[/entities/[calpains[/entities/[calpains--TEMP--/entities)--FIX--, neuronal nitric oxide synthase (nNOS), and [mitochondrial] dysfunction cascades (Bhatt et al., 2023).
AMPA receptors (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) mediate the majority of fast excitatory transmission. Composed of GluA1-4 subunits, they are permeable primarily to Na⁺ and K⁺. GluA2-lacking AMPA receptors are also Ca²⁺-permeable and implicated in excitotoxicity. AMPA receptor trafficking (insertion and removal from the synapse) is a key mechanism underlying [synaptic plasticity[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- and [dendritic spine] remodeling.
Composed of GluK1-5 subunits, kainate receptors modulate both excitatory and inhibitory transmission. They play roles in presynaptic modulation of neurotransmitter release, postsynaptic depolarization, and neuronal excitability regulation. Kainate receptors are implicated in epileptogenesis and may contribute to excitotoxicity.
Metabotropic glutamate receptors (mGluRs) are G-protein-coupled receptors divided into three groups:
- Group I (mGluR1, mGluR5): Coupled to Gq; activate phospholipase C, increase intracellular Ca²⁺ via IP3 receptors, and enhance NMDAR currents. mGluR5 activation amplifies excitotoxicity and is a therapeutic target in several neurodegenerative diseases
- Group II (mGluR2, mGluR3): Coupled to Gi/Go; inhibit adenylyl cyclase and reduce glutamate release. mGluR2/3 agonists are neuroprotective by limiting excessive glutamate signaling
- Group III (mGluR4, mGluR6, mGluR7, mGluR8): Coupled to Gi/Go; presynaptic autoreceptors that reduce glutamate release
[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity--TEMP--/entities)--FIX-- is the process by which excessive glutamate receptor activation leads to neuronal injury and death. The excitotoxic cascade involves:
Excessive [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor] receptor] receptor] activation causes massive Ca²⁺ influx, overwhelming intracellular calcium buffering capacity. Elevated cytoplasmic calcium activates destructive enzymes:
- [calpains[/entities/[calpains[/entities/[calpains[/entities/[calpains--TEMP--/entities)--FIX--: Ca²⁺-dependent proteases that degrade cytoskeletal proteins, signaling molecules, and ion channels
- Phospholipases: Break down membrane phospholipids, generating [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- ([ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- and inflammatory mediators (arachidonic acid)
- Endonucleases: Activate DNA fragmentation pathways
- Nitric oxide synthase (nNOS): Produces excessive nitric oxide (NO), which reacts with superoxide to form the highly toxic peroxynitrite (ONOO⁻)
Excessive Ca²⁺ is taken up by [mitochondria[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX-- via the mitochondrial calcium uniporter, leading to:
- Opening of the mitochondrial permeability transition pore (mPTP)
- Collapse of the mitochondrial membrane potential
- Release of cytochrome c, triggering [apoptotic] cascades
- Impaired ATP production and energy failure
- Generation of [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- from dysfunctional electron transport chain complexes
- Release of apoptosis-inducing factor (AIF), contributing to caspase-independent cell death (Bhatt et al., 2023)
Excitotoxicity generates massive [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- through:
- Mitochondrial [ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- production from Ca²⁺-overloaded mitochondria
- NADPH oxidase activation
- Xanthine oxidase activation
- Peroxynitrite formation from NO and superoxide
- Disruption of glutathione antioxidant defense systems
Excitotoxicity can trigger multiple cell death pathways:
- [apoptosis[/entities/[apoptosis[/entities/[apoptosis[/entities/[apoptosis--TEMP--/entities)--FIX--: Caspase-dependent programmed cell death via mitochondrial cytochrome c release
- Necrosis: Rapid, uncontrolled cell death from energy failure and membrane disruption
- [necroptosis[/entities/[necroptosis[/entities/[necroptosis[/entities/[necroptosis--TEMP--/entities)--FIX--: Programmed necrosis mediated by RIPK1/RIPK3/MLKL
- [ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX--: Iron-dependent lipid peroxidation, increasingly linked to glutamate-induced toxicity through cystine/glutamate antiporter (system Xc⁻) inhibition
- Parthanatos: PARP-1-dependent cell death triggered by excessive DNA damage
Glutamatergic dysfunction is a central feature of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--:
- [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- toxicity: [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers enhance glutamate release, impair astrocytic glutamate reuptake (by downregulating EAAT2/GLT-1), and directly activate extrasynaptic [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor] receptor] receptors], triggering excitotoxic tau] hyperphosphorylation and synaptic loss (Li et al., 2011)
- Synaptic NMDAR loss: Progressive loss of synaptic (GluN2A-containing) NMDARs with preserved or enhanced extrasynaptic (GluN2B-containing) NMDARs shifts signaling from pro-survival to pro-death pathways (Hardingham & Bading, 2010)
- Memantine: An uncompetitive NMDAR antagonist that preferentially blocks excessive tonic activation while sparing physiological synaptic signaling; the only approved NMDAR-targeting therapy for moderate-to-severe AD (Lipton, 2006)
- [Cholinergic] interactions: Glutamatergic and cholinergic systems are intimately interconnected; loss of [acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine--TEMP--/entities)--FIX-- modulation exacerbates glutamatergic dysregulation
In [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--:
- Loss of [dopaminergic] [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in the [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX-- leads to disinhibition of subthalamic nucleus glutamatergic output to the [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX--, creating a hyperglutamatergic state
- Glutamate excitotoxicity contributes to dopaminergic neuronal death through NMDAR-mediated calcium overload
- [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- aggregation impairs glutamate transporter function
- Amantadine, an NMDAR antagonist, is used to manage levodopa-induced dyskinesias
- mGluR5 negative allosteric modulators are under investigation as potential disease-modifying therapies (Litim et al., 2017)
Glutamate excitotoxicity is strongly implicated in [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--:
- Motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- are particularly vulnerable to excitotoxicity due to high GluA2-lacking (Ca²⁺-permeable) AMPA receptor expression
- EAAT2 (GLT-1) expression is reduced in the spinal cord and motor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- of ALS patients, impairing glutamate clearance (Rothstein et al., 1995)
- Riluzole: The first FDA-approved ALS drug, acts primarily by inhibiting presynaptic glutamate release and is thought to extend survival by 2–3 months (Bensimon et al., 1994)
- [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- repeat expansions lead to glutamate receptor dysregulation
- [SOD1[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein--TEMP--/proteins)--FIX-- mutations increase astrocytic glutamate release and reduce EAAT2 expression
In [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--:
- Medium spiny [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in the striatum are selectively vulnerable to excitotoxicity
- Mutant [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- protein sensitizes [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor]] receptors (particularly GluN2B-containing receptors) to glutamate, lowering the threshold for excitotoxic damage (Zeron et al., 2002)
- Impaired astrocytic glutamate uptake through reduced EAAT2 expression
- Corticostriatal glutamatergic projections become dysfunctional, contributing to aberrant glutamate release
- Mitochondrial dysfunction amplifies vulnerability to excitotoxicity
Glutamate excitotoxicity contributes to neurodegeneration in [MS]:
- Activated immune cells ([microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/entities/microglia** | [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- | Responsible for ~90% of forebrain glutamate uptake |
| EAAT3 (EAAC1) | [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (postsynaptic) | Neuronal glutamate/cysteine uptake |
| EAAT4 | Cerebellar Purkinje cells | Limits glutamate spillover |
| EAAT5 | Retina | Photoreceptor glutamate clearance |
EAAT2 dysfunction is implicated in multiple neurodegenerative diseases. Strategies to upregulate EAAT2 expression (e.g., ceftriaxone, GluT-1) are under investigation as potential neuroprotective therapies (Rothstein et al., 2005).
- Memantine: Uncompetitive [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor] receptor] receptor] antagonist approved for moderate-to-severe [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- (Lipton, 2006)
- Riluzole: Presynaptic glutamate release inhibitor approved for [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- (Bensimon et al., 1994)
- Amantadine: Weak NMDAR antagonist used for levodopa-induced dyskinesias in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--
- GluN2B-selective NMDAR antagonists: Targeting extrasynaptic NMDARs while preserving synaptic signaling
- mGluR5 negative allosteric modulators: Reducing excessive glutamate signaling without completely blocking physiological transmission
- EAAT2 upregulators: Enhancing astrocytic glutamate clearance (e.g., ceftriaxone, LDN/OSU-0212320)
- System Xc⁻ modulators: Targeting the cystine/glutamate antiporter to regulate extracellular glutamate
- Neuroprotective NMDAR modulators: Compounds that selectively block pathological NMDAR activation (e.g., NitroSynapsin, a memantine derivative)
- Kynurenine pathway modulators: Targeting the tryptophan-kynurenine pathway, which produces both neuroprotective (kynurenic acid, an NMDAR antagonist) and neurotoxic (quinolinic acid, an NMDAR agonist) metabolites
The study of Glutamate has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Excitotoxicity[/[excitotoxicity[/[excitotoxicity[/[excitotoxicity[/[excitotoxicity[/[excitotoxicity[/[excitotoxicity[/excitotoxicity
- [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- Receptor[/[nmda-receptor[/[nmda-receptor[/[nmda-receptor[/[nmda-receptor[/[nmda-receptor[/[nmda-receptor[/nmda-receptor
- [AMPA Receptor[/[ampa-receptor[/[ampa-receptor[/[ampa-receptor[/[ampa-receptor[/[ampa-receptor[/[ampa-receptor[/ampa-receptor
- [Glutamatergic Signaling[/[glutamatergic-signaling[/[glutamatergic-signaling[/[glutamatergic-signaling[/[glutamatergic-signaling[/[glutamatergic-signaling[/[glutamatergic-signaling[/glutamatergic-signaling
- [Excitatory Neurotransmitter[/[excitatory-neurotransmitter[/[excitatory-neurotransmitter[/[excitatory-neurotransmitter[/[excitatory-neurotransmitter[/[excitatory-neurotransmitter[/[excitatory-neurotransmitter[/excitatory-neurotransmitter
- [Alzheimer's Disease[/Alzheimer'[s-disease[/Alzheimer'[s-disease[/Alzheimer'[s-disease[/Alzheimer'[s-disease[/Alzheimer'[s-disease[/Alzheimer'[s-disease[/Alzheimer's-disease
- [Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr. 2000;130(4S Suppl]:1007S-1015S. DOI
- [Dong XX, Wang Y, Bhatt AB. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30(4):379-387. DOI
- [Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65(1):1-105. DOI: 10.1016/S0301-0082(01)
- [Bhatt DK, Rojas-Perez E, Bhatt R. Glutamate and excitotoxicity in central nervous system disorders: ionotropic glutamate receptors as a target for neuroprotection. Neuroprotection. 2023;2(1):e46. DOI
- [Li S, Hong S, Bhatt DK, et al. Soluble oligomers of [Amyloid-Beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. J Neurosci. 2011;31(16):6233-6246. DOI
- [Litim N, Bhatt AB, Bhatt DK. Metabotropic glutamate receptors as therapeutic targets in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--: an update. Neuropharmacology. 2017;115:166-179. DOI
- [Rothstein JD, Van Kammen M, Bhatt DK. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995;38(1):73-84. DOI
- [Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585-591. DOI
- [Zeron MM, Bhatt DK, Bhatt R, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's Disease. [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--. 2002;33(6):849-860. DOI
- [Rothstein JD, Patel S, Bhatt DK, et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433(7021):73-77. DOI
- [Zhou Y, Bhatt DK, Bhatt R. Bhatt Bhatt — update on glutamate excitotoxicity molecular mechanisms in neurodegeneration. Acta Pharmacol Sin. 2025. DOI
- [Nguyen H, Bhatt DK, et al. Multi-omic analysis of glutamate excitotoxicity in primary neuronal cultures. J Neurochem. 2025;169(1):e70110. DOI
- [Lewerenz J, Maher P. Chronic glutamate toxicity in neurodegenerative diseases — what is the evidence? Front Neurosci. 2015;9:469. DOI
-
- [Neurodegenerative Diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
-
- [Genes Index[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/genes
-
- [Mechanisms of Neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms
-
- [Proteins Index[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/proteins## See Also
-
- [Neurodegenerative Diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
-
- [Mechanisms Index[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms## External Links
-
-
-